Amgen: Colorectal Neoplasms trials

The registry lists 37 Colorectal Neoplasms studies with Amgen as lead sponsor. 2 are open to participants now and 22 have results posted.

Phase 1 9Phase 2 14Phase 3 10No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid TumorsRecruitingNCT07094113Phase 1
• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C MutationRecruitingNCT06252649Phase 3
• Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C MutationCompletedNCT05198934Phase 3Results posted
• Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal CancerCompletedNCT03362177Phase 3Results posted
• Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesCompletedNCT03256344Phase 1Results posted
• Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer PatientsCompletedNCT01732783Results posted
• Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced AnaemiaCompletedNCT01444456Results posted
• Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal CancerCompletedNCT01412957Phase 3Results posted
• ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal CancerCompletedNCT01001377Phase 3Results posted
• PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation StudyCompletedNCT00911170Phase 3Results posted
• PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) TumorsCompletedNCT00819780Phase 2Results posted
• Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer StudyCompletedNCT00630786Phase 1/2Results posted
• Effect of Panitumumab on the Pharmacokinetics of IrinotecanCompletedNCT00563316Phase 1Results posted
• Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal CancerCompletedNCT00508404Phase 2Results posted
• SPIRITT - Second-Line Panitumumab Irinotecan Treatment TrialCompletedNCT00418938Phase 2Results posted
• Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to TreatmentCompletedNCT00411450Phase 2Results posted
• PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine EfficacyCompletedNCT00364013Phase 3Results posted
• Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy AloneCompletedNCT00339183Phase 3Results posted
• Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based TherapyCompletedNCT00332163Phase 2Results posted
• PACCE: Panitumumab Advanced Colorectal Cancer Evaluation StudyCompletedNCT00115765Phase 3Results posted
• Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal CancerCompletedNCT00113763Phase 3Results posted
• Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal CancerCompletedNCT00111761Phase 2Results posted
• Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal CancerCompletedNCT00089635Phase 2Results posted
• Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin ChemotherapyCompletedNCT00083616Phase 2Results posted
• A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT06131398Phase 1
• Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic CancersTerminatedNCT04117958Phase 1
• ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st LineCompletedNCT02624895
• Safety Study of AMG 228 to Treat Solid TumorsTerminatedNCT02437916Phase 1
• Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORRCompletedNCT02322736
• Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in EuropeCompletedNCT01791361
• European Physician Survey of EGFR Inhibitor Prescribing PatternsCompletedNCT01652833
• Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver MetastasesCompletedNCT00866944Phase 2
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal CarcinomaCompletedNCT00752570Phase 2
• Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal CancerCompletedNCT00625651Phase 1/2
• Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal CancerCompletedNCT00327119Phase 2
• Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal CancerCompletedNCT00113776Phase 2
• Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal CancerCompletedNCT00101894Phase 1